Senecavirus A VLP Assembly via Segmented Plasmid Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing virus-like particles (VLPs) of Senecavirus A are inefficient in terms of expression and assembly, limiting their effectiveness as vaccines and diagnostic reagents.
Innovation Solution
A method involving the construction of recombinant plasmids encoding structural proteins VP0, VP1, and VP3, followed by expression, purification, and assembly of these proteins using specific enzymes and buffers to form VLPs, which are then used in vaccine and diagnostic reagent preparations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used to produce VLPs of Senecavirus A, then the production process is simple, but the expression level and assembly efficiency are inefficient
Solution Approach 1:
The patent divides the viral genome into separate expression cassettes for VP0, VP1, and VP3 proteins, each expressed independently in different bacterial strains. This segmentation allows optimized expression of each protein component, improving overall assembly efficiency while maintaining manageable process complexity through modular design.
Solution Approach 2:
The patent introduces a recombinant plasmid vector system as an intermediary carrier to facilitate the expression and assembly of VLPs. The plasmid vector mediates between the genetic information and the protein assembly process, enabling controlled expression and improving assembly efficiency through standardized molecular biology techniques.
2Reliability
If conventional methods are used to produce VLPs of Senecavirus A, then the production cost is low, but the immunogenicity is insufficient
Solution Approach 1:
The patent optimizes expression parameters by using specific bacterial strains (E. coli and Bacillus subtilis) with different expression systems, controlling temperature, pH, and induction conditions. These parameter changes enhance the expression level of structural proteins, thereby improving VLP assembly and immunogenicity while maintaining cost-effectiveness through scalable production.
Solution Approach 2:
The patent creates composite VLP structures by assembling multiple protein components (VP0, VP1, VP3) in specific stoichiometric ratios within a standardized capsid architecture. This composite approach ensures proper folding and assembly, enhancing immunogenicity while maintaining production efficiency through modular protein design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly improves the expression level and assembly efficiency of VLPs, enhancing their immunogenicity and utility in vaccine development and diagnostics.
Implementation Method 1
assembling the virus-like particle of the Senecavirus A
Data Source
AI summary
A virus-like particle of Senecavirus A, the particle including a structural protein VP0, a structural protein VP1 and a structural protein VP3. The structural protein VP0 is encoded by a gene sequence represented by SEQ ID NO: 1. The structural protein VP1 is encoded by a gene sequence represented by SEQ ID NO: 2. The structural protein VP3 is encoded by a gene sequence represented by SEQ ID NO: 3.